In News

Oculogica announces patent issued for detection and diagnosis of elevated intracranial pressure via eye-tracking.

Oculogica, a neuro-diagnostic company, has been issued a patent for its novel neuro-optic tracking device, the EyeBOXCNS™, to detect elevated intracranial pressure via eye-tracking. Continued elevation of ICP is believed to be the cause of Second Impact Syndrome, which is sudden death that occurs when sports players return to play in a concussed state and suffer a second blow to the head. An eye-tracking based test for elevated ICP as a part of a concussion test are promising developments for athletes, the military, trauma patients and the medical community that serves them.

Minnesota Daily: Clinical trial works to provide treatment for brain injuries